PORT 7
Alternative Names: PORT-7; TT-4Latest Information Update: 07 May 2025
At a glance
- Originator Impetis Biosciences
- Developer Tarus Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Adenosine A2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 29 Apr 2025 Pharmacodynamics data from preclinical studies in Solid tumors released by Portage Biotech
- 28 Mar 2025 Tarus Therapeutics withdraws prior to enrollment a phase I/II trial (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Solid tumors (PO) (NCT04976660)
- 27 Mar 2025 Pharmacodynamics data from preclinical studies in Solid tumors released by Portage Biotech